scholarly journals Course and pattern of venous thromboembolism in ovarian cancer patients

2021 ◽  
Author(s):  
Suwanit Therasakvichya ◽  
Wanniga Saengsuri
Keyword(s):  
Ovarian Cancer ◽  
Venous Thromboembolism ◽  
Cancer Patients

The timing of venous thromboembolism in ovarian cancer patients: A nationwide Danish cohort study

2021 ◽  
Author(s):  
Henriette Strøm Kahr ◽  
Ole B. Christiansen ◽  
Signe Juul Riddersholm ◽  
Inger L. Gade ◽  
Christian Torp‐Pedersen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cohort Study ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Danish Cohort

Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy

2021 ◽  
Author(s):  
Derman Basaran ◽  
Thomas Boerner ◽  
Jessa Suhner ◽  
Dib Sassine ◽  
Ying Liu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Venous Thromboembolism ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients

VENOUS THROMBOEMBOLISM INCIDENCE IN OVARIAN CANCER PATIENTS

2003 ◽  
Vol 13 (Suppl 1) ◽  
pp. 44.3-45
Author(s):  
L. Mereu ◽  
S. Salamano ◽  
E. Preti ◽  
D. Coscia ◽  
F. Piovella ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Venous Thromboembolism ◽  
Cancer Patients

PO-11 Venous thromboembolism in ovarian cancer patients: a nationwide Danish cohort study

2021 ◽  
Vol 200 ◽  
pp. S24
Author(s):  
H.S. Kahr ◽  
O.B. Christiansen ◽  
S.J. Riddersholm ◽  
I.L. Gade ◽  
C. Torp-Pedersen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cohort Study ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Danish Cohort

Stratification of Venous Thromboembolism Risk in Ovarian Cancer Patients During Chemotherapy

2009 ◽  
Vol 19 (1) ◽  
pp. 79-83 ◽  
Author(s):  
Liliana Mereu ◽  
Saverio Tateo ◽  
Catherine Klersy ◽  
Eva Martinotti Gabellotti ◽  
Franco Polatti
Keyword(s):  
Ovarian Cancer ◽  
Deep Vein Thrombosis ◽  
Prognostic Factors ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
First Line ◽  
Susceptible Population ◽  
Vein Thrombosis ◽  
Multivariable Regression ◽  
Deep Vein

Background:The prevalence of venous thromboembolism (VTE) in ovarian cancer during first-line chemotherapy (CHT) ranges between 6.4% and 10.6%. Identification of the susceptible population is crucial for effective thromboprophylaxis.Methods:We performed a retrospective study of all our patients with epithelial ovarian cancer who underwent ambulatory first-line CHT between 1990 and 2004. Data were collected regarding age, body mass index (BMI), previous deep vein thrombosis, pulmonary embolism (PE), menopause status, FIGO stage, grade, histology, type of surgery, residual disease, and CHT. Univariable and multivariable regression analyses were performed to assess independent prognostic factors for VTE/PE to calculate a prognostic index (PI).Results:Of 203 patients, 16 (7.8%) had symptomatic VTE: 15 deep vein thrombosis and 1 PE. Multivariable regression analysis found that age (P = 0.01), BMI (P = 0.01), and stage (P = 0.05) were independent prognostic factors for VTE. Age, BMI, and stage were used to calculate the PI: 0.285 × age + 0.555 × BMI + 1.110 × stage. The PI was dichotomized according to its median cutoff (5.8) to define a low (3.8% at 6 months) and a high (11.3%) VTE incidence group.Conclusions:Age, BMI, and stage permit to identify ovarian cancer patients with a high risk in developing symptomatic VTE during CHT.

Platelet Function in Ovarian Cancer

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4656-4656
Author(s):  
Shuju Feng ◽  
Michael H. Kroll ◽  
Alpa M. Nick ◽  
Anil Sood ◽  
Vahid Afshar-Kharghan
Keyword(s):  
Ovarian Cancer ◽  
Venous Thromboembolism ◽  
Platelet Aggregation ◽  
Cancer Patients ◽  
Room Temperature ◽  
Ovarian Tumors ◽  
Benign Tumors ◽  
Blood Samples ◽  
Benign Ovarian Tumors ◽  
Aggregation Of Platelets

Abstract A significant number of patients with ovarian cancer develop venous thromboembolism that is associated with a worse prognosis. The etiology of an increased frequency of venous thrombosis in cancer patients is not clear, and various hypotheses, including the presence of hyperreactive platelets, have been postulated. Hyperreactive platelets have a lower threshold for aggregation, and hence there is a higher number of degranulated platelets in circulation and a higher concentration of platelet granular contents in plasma. We compared ADP- and collagen-induced platelet aggregation in patients with ovarian cancer to those in patients with benign ovarian tumors. To reduce the effect of confounding factors such as surgery or chemotherapy, all blood samples were collected prior to any surgical interventions or chemotherapy. To detect hyperreactivity of platelets, we used both low and high doses of platelet agonists. To evaluate platelet preactivation at baseline, we measured the plasma concentration of b-thromboglobulin (b-TG) and platelet factor-4 (PF-4) as markers of platelet α granule secretion. All studies were approved by the Institutional Review Boards of the University of Texas, M.D. Anderson Cancer Center. Whole blood samples were collected from 34 patients with ovarian cancer and 19 patients with benign ovarian tumors into sodium citrate anticoagulant and processed within 2 hours after collection. Platelet rich plasma (PRP) was prepared by 15 min of 850 rpm centrifugation at room temperature. Aggregation studies were conducted in a light transmission aggregometer (Bio/Data Corporation), using ADP (at 2mM and 20 mM) and collagen (at 19 mg/ml and 190 mg/ml). Platelet poor plasma (PPP) was prepared by centrifuging PRP samples at 2500 rpm for 20 min at room temperature. All PPP samples were stored at -80ºC and the quantity of b-TG and PF-4 was determined by ELISA. We found that platelets isolated from ovarian cancer patients showed aggregation responses similar to platelets from patients with benign ovarian tumors (Figure 1). There was a statistically significant difference in the high-dose collagen-induced platelet aggregation between cancer and benign tumor samples, with increased aggregation of platelets from patients with benign tumors (79 ± 4.9%) in comparison to aggregation of platelets from cancer platelets (69 ± 6.3%). To investigate preactivation of platelets in cancer patients, we measured b-TG and PF-4 in PPP samples. We did not detect a higher concentration of b-TG and PF-4 in cancer PPP samples (Figure 2). In fact, PPP from cancer patients had a lower concentration of both α granule constituents. In the case of PF-4, the difference was statistically significant (9.8 ± 1.5 ng/ml for cancer patients versus 11.7 ± 1.7 ng/ml for patients with non-malignant tumors). We conclude that platelets from ovarian cancer patients are not hyperreactive and are not degranulated or preactivated. Links between ovarian cancer, venous thromboembolism and platelets may be absent or may involve non-hemostatic platelet functions. Figure 1. Figure 1. Figure 2. Figure 2. Disclosures No relevant conflicts of interest to declare.

scholarly journals Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis

Cancers ◽  
2021 ◽  
Vol 13 (18) ◽  
pp. 4603
Author(s):  
Michael Saerens ◽  
Emiel A. De Jaeghere ◽  
Heini Kanervo ◽  
Nele Vandemaele ◽  
Hannelore Denys ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ovarian Cancer ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Absolute Risk ◽  
Meta Analysis ◽  
Additional Risk Factor ◽  
The Absolute

Thromboembolic events are the second cause of death in cancer patients. In ovarian cancer, 3–10% of patients present with venous thromboembolism (VTE), but the incidence may rise to 36% along the disease course. Bevacizumab is a monoclonal antibody directed against vascular endothelial-derived growth factor, and in in vitro studies it showed a predisposition to hemostasis perturbation, including thrombosis. However, in vivo and clinical studies have shown conflicting results for its use as a treatment for ovarian cancer, so we conducted a systematic review and meta-analysis on the risk of arterial thromboembolism (ATE) and VTE in ovarian cancer patients treated with bevacizumab. The review comprised 14 trials with 6221 patients: ATE incidence was reported in 5 (4811 patients) where the absolute risk was 2.4% with bevacizumab vs. 1.1% without (RR 2.45; 95% CI 1.27–4.27, p = 0.008). VTE incidence was reported in 9 trials (5121 patients) where the absolute risk was 5.4% with bevacizumab vs. 3.7% without (RR 1.32; 95% CI 1.02–1.79, p = 0.04). Our analysis showed that the risk of arterial and venous thromboembolism increased in patients treated with bevacizumab. Thrombolic events (TEs) are probably underreported, and studies should discriminate between ATE and VTE. Bevacizumab can be considered as an additional risk factor when selecting patients for primary prophylaxis with anticoagulants.

Sign in / Sign up

Export Citation Format

Share Document